Pharmatech Oncology
Caris Life Sciences is a pioneer in molecular science and precision medicine, dedicated to improving patient outcomes through innovative solutions, comprehensive molecular profiling, and advanced AI and machine learning technologies. Founded in 2008, the company offers extensive molecular testing services, including blood-based and tissue-based assays, to help physicians and researchers better detect, diagnose, and treat cancer and other diseases. With a large-scale clinico-genomic database and a global presence, Caris is committed to revolutionizing healthcare and advancing personalized treatment options.
Industries
Nr. of Employees
Very Large (1000+)
Patents
System and method for determining individualized medical intervention for a disease state
US-9383365-B2
View DetailsSystem and method for determining individualized medical intervention for a disease state
US-9372193-B2
View Details
System and method for determining individualized medical intervention for a disease state
US-9383365-B2
View DetailsSystem and method for determining individualized medical intervention for a disease state
US-9372193-B2
View DetailsProducts
Blood-based whole-exome and whole-transcriptome sequencing assay (liquid biopsy)
A circulating nucleic acid sequencing assay that performs whole-exome and whole-transcriptome analysis from a blood sample to provide comprehensive molecular insights and enable serial monitoring.
Comprehensive tissue molecular profiling (WES/WTS with proteomics and AI interpretation)
An integrated tissue-based molecular profiling service combining whole-exome and whole-transcriptome sequencing with protein analysis and AI-derived interpretations to support therapy selection.
AI-powered molecular analytics platform
A software and analytics platform that applies machine learning to linked molecular and clinical data to classify tumors, predict response, and generate clinical interpretations and signatures.
Prospectively matched clinico-genomic research dataset and platform
A prospectively generated, EHR-enabled research dataset and platform that links molecular, imaging and curated clinical data to enable cohort discovery, regulatory-grade evidence generation, and clinical development support.
Blood-based whole-exome and whole-transcriptome sequencing assay (liquid biopsy)
A circulating nucleic acid sequencing assay that performs whole-exome and whole-transcriptome analysis from a blood sample to provide comprehensive molecular insights and enable serial monitoring.
Comprehensive tissue molecular profiling (WES/WTS with proteomics and AI interpretation)
An integrated tissue-based molecular profiling service combining whole-exome and whole-transcriptome sequencing with protein analysis and AI-derived interpretations to support therapy selection.
AI-powered molecular analytics platform
A software and analytics platform that applies machine learning to linked molecular and clinical data to classify tumors, predict response, and generate clinical interpretations and signatures.
Prospectively matched clinico-genomic research dataset and platform
A prospectively generated, EHR-enabled research dataset and platform that links molecular, imaging and curated clinical data to enable cohort discovery, regulatory-grade evidence generation, and clinical development support.
Services
Laboratory and interpretation services performing whole-exome and whole-transcriptome sequencing on tissue and blood, combined with proteomic and imaging analyses to produce integrated molecular reports for clinical decision-making.
Discovery services combining multi-omic interrogation of patient-derived tissue with aptamer-based proteomic profiling and in vitro validation workflows to identify and characterize novel therapeutic targets.
Operational services that match biomarker-positive patients to appropriate clinical trials and enable rapid site activation and enrollment to reduce time-to-enroll.
Provision of a prospectively generated, EHR-enabled research dataset and platform that links molecular, imaging and curated clinical data for cohort discovery, regulatory-grade RWE generation, and collaborative research programs.
Analytics services over linked molecular and clinical-outcomes data using AI/ML to support biomarker discovery, cohort generation, predictive signature development, and translational research.
Integration services enabling electronic ordering, status tracking and structured results delivery into EHR/EMR systems to streamline clinical workflows and reduce manual data entry.
Laboratory and interpretation services performing whole-exome and whole-transcriptome sequencing on tissue and blood, combined with proteomic and imaging analyses to produce integrated molecular reports for clinical decision-making.
Discovery services combining multi-omic interrogation of patient-derived tissue with aptamer-based proteomic profiling and in vitro validation workflows to identify and characterize novel therapeutic targets.
Operational services that match biomarker-positive patients to appropriate clinical trials and enable rapid site activation and enrollment to reduce time-to-enroll.
Provision of a prospectively generated, EHR-enabled research dataset and platform that links molecular, imaging and curated clinical data for cohort discovery, regulatory-grade RWE generation, and collaborative research programs.
Analytics services over linked molecular and clinical-outcomes data using AI/ML to support biomarker discovery, cohort generation, predictive signature development, and translational research.
Integration services enabling electronic ordering, status tracking and structured results delivery into EHR/EMR systems to streamline clinical workflows and reduce manual data entry.
Expertise Areas
- Comprehensive molecular profiling (WES/WTS) for tissue and blood
- Multi-omic integration (genomics, transcriptomics, proteomics, imaging)
- Liquid biopsy and serial circulating nucleic acid monitoring
- Aptamer-based proteomics and biomarker discovery
Key Technologies
- Whole-exome sequencing (WES)
- Whole-transcriptome sequencing (WTS)
- Circulating nucleic acid sequencing (liquid biopsy / ctDNA)
- Aptamer-based proteomic profiling
News & Updates
Caris Life Sciences files registration statement for a potential initial public offering, signaling growth and market confidence.
Caris to showcase extensive research collaborations and innovations in precision oncology at the 2025 American Society of Clinical Oncology Annual Meeting.
David Halbert, CEO of Caris Life Sciences, considers going public again amid rapid demand for next-generation sequencing in cancer.
Caris partners with Incyte to leverage molecular data and AI for drug discovery and clinical trial optimization in oncology.
Caris was honored as the 2022 Arizona Bioscience Company of the Year by AZBio for its leadership in molecular science and healthcare innovation.
Caris Life Sciences files registration statement for a potential initial public offering, signaling growth and market confidence.
Caris to showcase extensive research collaborations and innovations in precision oncology at the 2025 American Society of Clinical Oncology Annual Meeting.
David Halbert, CEO of Caris Life Sciences, considers going public again amid rapid demand for next-generation sequencing in cancer.
Caris partners with Incyte to leverage molecular data and AI for drug discovery and clinical trial optimization in oncology.
Caris was honored as the 2022 Arizona Bioscience Company of the Year by AZBio for its leadership in molecular science and healthcare innovation.